Dr. D’Armiento and Dr. Goldklang Funded for Alpha-1 Antitrypsin Deficiency Studies

Congratulations to Dr. D’Armiento and Dr. Goldklang, who both have recently been awarded grants for their studies in Alpha-1 antitrypsin deficiency (AATD), which is the first identified heritable cause of chronic obstructive pulmonary disease (COPD).

Dr. D’Armiento’s study, “Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease,” with direct costs totaling $585,120 in the first year, is funded by the National Institutes of Health/National Heart, Lung, and Blood Institute.  The six-year grant will establish a prospective clinical cohort of patients with AATD.  Dr. D’Armiento is the main principal investigator for this multi-center grant, with Drs. Gebhard Wagener and Monica Goldklang participating as co-investigators. 

Dr. Goldklang’s grant award, from the Alpha-1 Foundation, will support pre-clinical studies to develop novel functional imaging approaches in AATD. Titled “In vivo functional imaging of alpha-1 antitrypsin deficiency,” this grant’s direct costs will total $200,000 over two years. The Alpha-1 Foundation is a nonprofit corporation that promotes research and development of therapies to improve quality of life for people with AATD.

Congratulations, Dr. D’Armiento and Dr. Goldklang!